n the first half of 2025, the National Medical Products Administration (NMPA) approved 53 new chemical drugs, representing a 43% increase compared to the same period in 2024. Among them, 27 were innovative chemical drugs.
This impressive achievement not only reflects the strength of China's pharmaceutical innovation but also serves as the best validation for forward-looking investors. Amid this surging wave of innovation, Efung Capital and its partner pharmaceutical companies have added a brilliant chapter to this remarkable scorecard with their outstanding performance.
01 Portfolio Company Listing and Financing Progress
Orygen Biotech
Officially Launches Issuance Process
On the evening of September 22, Orygen Biotech disclosed its prospectus, issuance arrangements, and preliminary inquiry announcement on the Shanghai Stock Exchange website, officially launching the issuance process.
Atom Therapeutics
Atom Therapeutics Files for Hong Kong IPO with Post-Round Valuation of RMB 3.05 Billion
On September 15, Atom Therapeutics' Hong Kong IPO application was accepted, and its prospectus was officially made public. Since its establishment, Atom Therapeutics has undergone multiple financing rounds. Between 2023 and 2025, it completed a Series D financing round of RMB 552.2 million, achieving a post-money valuation of RMB 3.0522 billion.
Jiyin Biotech
Jiyin Biotech Completes Series A+ Financing
Recently, Shenzhen Jiyin Biotech Co., Ltd., focused on the development of universal cell therapies, completed a Series A+ financing round. As its core technology continues to be validated and matured, Jiyin Biotech is committed to expanding universal cell therapies into multiple therapeutic areas including oncology and autoimmune diseases, addressing diverse clinical needs, and effectively promoting the accessibility of cell immunotherapy.
Huiguan Biotech
Huiguan Biotech Completes Pre-A+ Financing
Recently, Wuhan Huiguan Biotech Co., Ltd. completed a Pre-A+ financing round. The funds will be primarily used for product R&D, market promotion, and team expansion, further consolidating the company's leading position in the high-end biomedical imaging field.
Xuanzhu Biopharma
Xuanzhu Biopharma IPO Receives CSRC Filing Approval
Recently, the International Cooperation Department of the China Securities Regulatory Commission (CSRC) issued a filing approval notice regarding the overseas issuance and "full circulation" of domestic unlisted shares of Xuanzhu Biopharma. According to the notice, Xuanzhu Biopharma plans to issue no more than 77,433,500 overseas listed ordinary shares for listing on the Hong Kong Stock Exchange, and 17 shareholders plan to convert a total of 93,368,496 domestic unlisted shares into overseas listed shares.
02 Portfolio Company Clinical and Commercialization Updates
Orygen Biotech
Recombinant Protein Technology Breakthrough and Integrated Development Innovation Forum Successfully Concluded
On the morning of September 5, the Recombinant Protein Technology Breakthrough and Integrated Development Innovation Forum & Aofumin® (Recombinant Human Serum Albumin Injection from Rice) Launch Conference was successfully held in Wuhan. The forum was co-hosted by the Chinese Society of Biotechnology and Wuhan Orygen Biotech Co., Ltd.
Baiyinnuo Biotech
Baiyinnuo NK Cell Expansion Kit Unlocks Higher Efficiency and Purity Cell Culture Solutions
Recently, Baiyinnuo Biotech launched a professional NK cell expansion kit, breaking through traditional technical bottlenecks, ensuring efficient NK cell expansion, providing reliable support for cell therapy, and helping this "natural immune guardian" benefit more patients.
Presence at BPI US 2025
From September 15-18, the world's largest bioprocess event—BioProcess International Conference & Exhibition (BPI)—was successfully held in Boston, USA. Dr. Zhao Xiaojian, CEO of Baiyinnuo Biotech, and Dr. Scott M Wheelwright, COO, attended the exhibition. Baiyinnuo Biotech set up a dedicated booth, showcasing its core products including serum-free media (MSC, PSC series), GMP-grade stem cell exosomes, and one-stop R&D services for biopharmaceutical companies.
Presence at BioCMC 2025: Exploring Biopharmaceutical Industrialization Frontiers
On September 4-5, BioCMC 2025, the 9th Baishi Biopharmaceutical CMC Technology Innovation Conference, was held in Suzhou. Baiyinnuo Biotech set up a dedicated booth, comprehensively presenting its core products and one-stop R&D services.
Xuanyu Medical
Multiple Hospitals Perform Surgeries Using Xuanyu Medical Technology
Recently, multiple hospitals successfully performed surgeries using Xuanyu Medical's RhythPulse® pulsed field ablation catheter for atrial fibrillation patients. These included Tongling People's Hospital, The Second Affiliated Hospital of Harbin Medical University, Beijing Ditan Hospital Affiliated to Capital Medical University, Zhujiang Hospital of Southern Medical University, Wuhan Yaxin General Hospital, Beijing Anzhen Hospital, Tianjin Medical University General Hospital, Xiangtan Central Hospital, Taizhou Central Hospital, Huai'an Huai'an Hospital, and The Second Affiliated Hospital of Wenzhou Medical University.
Tingke Technology
Wuhan Wuchang Hospital Completes Procedure Guided by Tingke's ICE
Recently, Professor Wang Liyue's team at Wuhan Wuchang Hospital successfully performed a left atrial appendage occlusion procedure on a patient at high risk of stroke after atrial fibrillation radiofrequency ablation, guided by the first domestic intracardiac echocardiography (ICE) system TINGSN Sonic Eyes 10.
Kening Bio
Important Progress in Osteoarthritis Treatment
Recently, Dr. Sun Zhexun, co-founder and CTO of Kening Biopharmaceutical Technology (Hangzhou) Co., Ltd., in collaboration with Professor Lawrence J. Bonassar and Professor David Putnam of Cornell University, published a research paper titled "Synthetic Lubrication of Bone Interfaces for Late-Stage Osteoarthritis Treatment" in Langmuir, a leading journal in materials science. The study reports for the first time a diblock copolymer capable of effectively lubricating the subchondral bone interface, offering a potential non-surgical treatment option for patients with late-stage osteoarthritis (OA).
Weimai Medical
Pioneering! "Three-in-One" Stent Visualization: 10ms Reconstruction, 99% Recognition Rate Disrupts Tradition
Recently, Weimai Medical, with its self-developed AI algorithms and non-rigid registration technology, achieved seamless fusion of multimodal data across underlying algorithms and system architectures, becoming the world's first enterprise to provide a "full-process stent visualization solution." The "three-in-one" stent visualization allows doctors to observe the stent status from multiple angles during surgery, flexibly switch modes according to different stage requirements, covering the entire cycle from preoperative planning to postoperative follow-up.
Weimai Medical Shines at 2025 CIFTIS, Interventional Robot Demonstrates "China Smart Manufacturing" New Quality Productivity
Recently, the 2025 China International Fair for Trade in Services (CIFTIS) grandly opened in Beijing's Shougang Park. Weimai Medical showcased its interventional robot in the core area, delivered a keynote speech, and signed a medical robot leasing project on-site, presenting the latest achievements of China's high-end medical equipment self-reliance to the world.
China Pharmaceutical News Information Association Leads Mainstream Media Group to Visit Weimai Medical
On September 19, the China Pharmaceutical News Information Association led a mainstream media group to Weimai Medical. Weimai Medical CEO Yang He warmly received the delegation, telling the inspiring story of Chinese high-end medical technology self-reliance.
Two Products Obtain CE Certification!
On September 23, in accordance with MDR 2017/745, multiple models of Weimai Medical's self-developed Taikon® DSA series and Phoenix® mobile C-arm series successfully obtained CE certification. This marks important recognition of Weimai Medical's product quality and technological capabilities, laying a solid foundation for further expansion into the global interventional diagnosis and treatment equipment market.
EZone Organizes Innovation Enterprises for Hong Kong Exchange to Promote International Development of Yizhuang Biopharmaceutical Industry
Recently, BIOHK2025 was successfully held at the Hong Kong Convention and Exhibition Centre. Under the coordination of the Economic and Technological Development Zone (EZone), Weimai Medical and other innovative enterprises formed the "Yizhuang Biopharmaceutical Delegation" to showcase Beijing Yizhuang's innovation strength and open stance.
Interventional Robot Invited as Model Enterprise to Co-create Future Catheter Room Blueprint with Top Cardiac Institutions
Recently, the China Heart Congress 2025 (CHC2025) was held at the China National Convention Center in Beijing. Weimai Medical, as an invited model enterprise in the interventional robotics track, deeply participated in the Future Innovative Catheter Room Model Seminar. The company's CTO Xie Jing delivered a speech on "Technological Progress of Cardiovascular Interventional Surgical Robots and Their Application in Future Catheter Rooms."
Aomo Pharma
Atom Therapeutics
Positive Results from Global Phase IIb/III Trial of Anti-Gout Drug ABP-671
On September 8, Atom Therapeutics announced very positive results from the global Phase IIb/III clinical trial of ABP-671 for the treatment of gout. The trial was a multicenter, randomized, double-blind, allopurinol-positive (Treat-to-Target) and placebo-controlled global study conducted across multiple countries and regions, with a 6-month primary evaluation period.
CUA 2025 Successfully Held
On September 4, the 32nd National Congress of Urology (CUA 2025) grandly opened at the Dalian International Conference Center. Atom Medical showcased its innovative extracorporeal shock wave lithotripsy products and solutions, engaging in in-depth exchanges with attending experts and scholars.
Hannuo Medical
Hannuo Medical Presents at CCCC 2025
From September 4-7, the 16th Annual Meeting of the Critical Care Medicine Branch of the Chinese Medical Association & China Critical Care Medicine Congress (CCCC 2025) was successfully held in Nanjing, Jiangsu. Hannuo Medical's portable支架 made its first public appearance, attracting significant attention from experts and clinicians.
Sino-German ECMO Technology Innovation and Industry Development Summit Successfully Held at Hannuo Medical
On September 12, the "New Era of Low-Altitude Medical Rescue: Sino-German ECMO Technology Innovation and Industry Development Summit" was successfully held at Hannuo Medical's headquarters in Bao'an, Shenzhen. Ms. Liu Yang, Chairman of Hannuo Medical, shared the strategic vision of "Lifemotion® ECMO's Systematic Layout in Three-Dimensional Rescue."
Tianqin Biotech
Multiple Experts Invited to Speak at 13th Annual Conference of Drug Toxicology
From September 11-13, the 13th Annual Conference of Drug Toxicology was held in Jiaxing, Zhejiang. Multiple experts from Tianqin Biotech were invited to deliver presentations at the main venue and various sub-forums, sharing their insights and experiences in drug non-clinical safety evaluation.
Norling Medical
Presents NO Full-Ecosystem Solution at CCCC 2025
From September 5-7, CCCC 2025 was held in Nanjing, Jiangsu. Norling Medical presented its NO full-ecosystem solution.
Precise Strategies to Break the Treatment Dilemma of ARDS
On September 22, the Third Quarter 2025 Academic Conference of the Critical Emergency Rescue Branch of the Shanghai Medical Association was successfully held at the Shanghai National Convention and Exhibition Center. Dr. Xing Shunpeng's special report on "Inhaled NO Therapy for ARDS Patients" systematically explained the key role of inhaled nitric oxide (iNO) in correcting hypoxemia and improving pulmonary vascular function.
Ying Minda
Showcases Intravascular Dual-Mode Imaging System at PCI Salon 2025
Recently, the "2025 Sichuan Coronary Intervention Salon & Complex Coronary Case Demonstration Meeting (PCI Salon 2025)" successfully concluded in Chengdu, Sichuan. During the meeting, Ying Minda showcased its intravascular dual-mode imaging system.
Ying Minda "Miniprobe" Deployed at Three Benchmark Hospitals in Shanxi
Recently, Ying Minda's self-developed miniprobe ultrasound endoscopy series was deployed at three benchmark hospitals in Shanxi Province—Shanxi Provincial People's Hospital, First Hospital of Shanxi Medical University, and Second Hospital of Shanxi Medical University—providing high-quality medical services to patients in Shanxi and surrounding areas.
Century Kangtai
2025 CCOS Series of Academic Activities Successfully Concluded
Recently, the 29th National Congress of Ophthalmology of the Chinese Medical Association (CCOS 2025) was held at the Hangzhou International Expo Center. Century Kangtai created a series of academic events under the theme "Century Light · Bright Future," focusing on new advances in refractive cataract surgery and optometry technology.
Professor Zhang Guangbin Shares Excellent Post-Market Data for Liangsian® Trifocal Plus IOL
Recently, at the CCOS 2025 conference, Professor Zhang Guangbin presented for the first time the post-market clinical data (as of August 31, 2025, n=127 eyes) of the Liangsian® Trifocal Plus IOL (D615L), showing steady improvement in postoperative vision.
Huahao Zhongtian
First Global Study of Utidelone Capsules Initiated
On September 11, Huahao Zhongtian announced the first patient dosing in the international multicenter Phase II/III clinical study (BG02-2502) of its core product Utidelone capsules (UTD2) for platinum-resistant advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
First Patient Dosed in Global Clinical Study of Utidelone Capsules for First-Line Treatment of Advanced Gastric Cancer
On September 12, Huahao Zhongtian announced the first patient dosing in the international multicenter Phase II/III clinical study (BG02-2404) of Utidelone capsules (UTD2) for first-line treatment of locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Breaking Through Pancreatic Cancer! Utidelone Receives Another FDA Orphan Drug Designation
On September 25, Huahao Zhongtian announced that its core product Utidelone received another Orphan Drug Designation from the U.S. FDA, this time for the treatment of pancreatic cancer. This is the third Orphan Drug Designation granted to Utidelone by the FDA, following breast cancer brain metastases and gastric cancer.
Key Synthetic Biology Genetically Engineered Bacteria Technology Granted U.S. PCT Patent
On September 19, Huahao Zhongtian announced that a key synthetic biology technology independently developed by the company was granted an invention patent by the U.S. Patent and Trademark Office. The patent covers a high-quality and efficient genetically engineered bacterium and a method for producing Utidelone using it.
HBM Holdings
Dr. Wang Jinsong Speaks at Legend Capital Forum
On September 10, the Legend Capital 2025 Annual CFO & CHO Joint Forum, themed "Goal-Driven, Breaking Through for Growth," was held in Beijing. Dr. Wang Jinsong, Founder, Chairman, and CEO of HBM Holdings, was invited as the first keynote speaker, sharing the development history and future trends of China's innovative drug industry.
Xunlu Bio
Research Results of Equecabtagene Autoleucel for Multiple Sclerosis Presented at 2025 ANA and ECTRIMS
On September 12, Xunlu Bio announced that research results from its fully human BCMA-targeted CAR-T cell therapy Equecabtagene Autoleucel (Eque-cel) for progressive multiple sclerosis (PMS) would be presented at the 2025 American Neurological Association (ANA) Annual Meeting and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, as a poster and oral presentation, respectively.
Global Strategic Partnership with Saibio to Jointly Advance Domestic Cell Therapy Integration Going Global
On September 9, Xunlu Bio and Saibio formally signed a global strategic cooperation agreement to jointly promote the integrated global expansion of domestic advanced cell therapy drug industry chains.
Landmark Release of 3-Year Follow-Up Data for CAR-T Product Fucaso® in Multiple Myeloma, Achieving Multiple Breakthroughs
On September 19, Xunlu Bio announced that the 36-month long-term follow-up data from the FUMANBA-1 study of its fully human BCMA-targeted CAR-T cell therapy product Fucaso® (Equecabtagene Autoleucel, Eque-cel) for relapsed/refractory multiple myeloma (R/R MM) was officially released during the International Myeloma Society (IMS) Annual Meeting.
Five CAR-T Products Pass Expert Review for Commercial Insurance Innovative Drug List, Including Xunlu Bio's Product
On September 20, the National Healthcare Security Administration announced that the expert review for the 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List had concluded. Five domestic CAR-T products passed the expert review, including Xunlu Bio's Equecabtagene Autoleucel.
Jingze Bio
Strategic Partnership with Kangzhe Pharma, Signing Commercialization Agreements for Multiple Core Products
Recently, Jingze Bio reached a strategic partnership with a subsidiary of Kangzhe Pharma, signing commercialization agreements for multiple core products to jointly expand domestic and international markets, injecting strong momentum into the company's product commercialization process.
Biaoxin Bio
Pre-IND Application for Global First-in-Class RSK Bifunctional Degrader GT818 Submitted to CDE for Advanced Malignancies
On September 18, Biaoxin Bio (Gluetacs Therapeutics) announced the successful submission of a Pre-IND application for its bifunctional degrader GT818, developed on the GlueTacs® platform, to the CDE. This marks the formal initiation of the dual China-US registration clinical development process.
Tiangang Yinuo
Two First-in-China Innovative Drugs Initiate Phase I Clinical Trials
Recently, a monoclonal antibody drug from Hefei Tiangang Immunotherapy Co., Ltd. initiated a Phase I clinical trial at Fudan University Shanghai Cancer Center, with the first patient enrolled and dosed. To date, Tiangang Yinuo has two innovative immunotherapies that are the only ones in China and tied for second globally in the field, now in clinical trials.
Invited to Attend the 3rd Hefei Biopharmaceutical Innovation and Industry Conference, Showcasing Immunotherapy Frontiers
From September 4-6, the 3rd Hefei Biopharmaceutical Innovation and Industry Conference was held in Hefei. Professor Tian Zhigang, founder of Hefei Tiangang Immunotherapy, along with Dr. Cao Guoshuai (VP of R&D) and Dr. Zheng Xiaohu (VP of Operations), were invited to attend and deliver presentations.
Provincial Party Secretary Liang Yanshun Visits Tiangang Yinuo to Inspect Innovative Product Achievements
On the morning of September 1, Provincial Party Secretary Liang Yanshun conducted research at the Hefei Comprehensive National Science Center Institute of Health and held a symposium, emphasizing the importance of high-level scientific innovation platforms.
KaiTuo Biotech
Collaborates with Tofflon to Explore Frontiers of RNA-LNP Drug CMC Processes
On September 25, Dr. Huang Ri, Head of LNP Formulation Process Development at KaiTuo Biotech, was invited to share on the full-process CMC development and targeted delivery solutions for mRNA-LNP drugs.
Collaborates with Zenuity Biotech's LNP Technology Platform to Accelerate Patent Commercialization
Recently, KaiTuo Biotech and Zenuity Biotech's lipid nanoparticle (LNP) delivery technology platform ViLNP® reached four external technology licensing agreements, covering multiple fields including mRNA tumor vaccines, metabolic diseases, in vivo CAR-T, and gene editing.
Kuanyue Orthopedics
Gaining Global Attention: Total Hip and Knee Replacement Solutions Lead Innovation Trends
Recently, Kuanyue Orthopedics frequently appeared on the international medical stage, participating in three major industry events: the ICJR Exhibition in Egypt, the SICOT World Orthopedic Congress, and the Peru Medical Expo, showcasing its cutting-edge products and system solutions in total hip and knee replacement.
Lingyi Biotech
Gaucher Disease AAV Gene Therapy LY-M001 Initiates Phase II Clinical Trial
Recently, Lingyi (Hangzhou) Biotech Co., Ltd. announced that the Phase II clinical trial of its self-developed LY-M001 injection for type I Gaucher disease has been officially initiated, rapidly advancing multicenter clinical research. This is the first AAV gene therapy drug for Gaucher disease in China to enter Phase II clinical trials.
Huanma Biotech
Macau SAR Investment Promotion Agency Delegation Visits Huanma Biotech
On September 19, a delegation led by Mr. Xie Yongqiang, Chairman of the Macau SAR Investment and Trade Promotion Institute, and Mr. Chen Zurong, Deputy Director of the Economic and Technological Development Bureau, visited Shanghai Huanma Biotech for exchange.
Strategic Partnership with Yinyan Technology to Explore AI-Empowered Drug R&D
Recently, Huanma Biotech and Yinyan Technology jointly announced a three-year strategic cooperation agreement to explore the deep application of AI agents in novel RNA drug R&D.
Zifu Medical
Digital Intelligence Empowers Health Management, Innovation Drives Discipline Development
From September 19-21, the 18th China Health Service Conference & 16th Academic Conference on Health Management of the Chinese Medical Association was successfully held in Chengdu. Zifu Medical, with its globally leading magnetically controlled capsule endoscopy technology, became a standout "digital intelligence leader."
Beimei Pharma
Anke Bio
Governor Wang Qingxian Inspects Anke Bio Booth at World Manufacturing Convention
On September 20, the 2025 World Manufacturing Convention opened at the Hefei Binhu International Convention Center. Anke Bio, as a leading biopharmaceutical enterprise in Anhui Province, was invited to exhibit for the fourth consecutive time.
Meizhong Shuanghe
"Precision PCI" Series Products Shine at CIFTIS
Recently, at CIFTIS 2025, Beijing Meizhong Shuanghe Medical Device Co., Ltd. showcased its "Precision PCI" series of innovative products.
Andao Pharma
First-in-Class Pan-Anemia Therapy Initiates First Phase III Clinical Trial
On September 11, the drug clinical trial registration and information disclosure platform showed that Andao Pharma registered a Phase III clinical trial of oral AND017 capsules for anemia in dialysis-dependent chronic kidney disease (DD-CKD) subjects.
Yinnuo Pharma
YN001 Phase Ib/IIa Clinical Trial Data Released Globally for the First Time
On September 1, at the 2025 European Society of Cardiology Congress (ESC Congress 2025) in Madrid, Spain, Yinnuo Pharma released the Phase Ib/IIa clinical trial data of YN001, the first innovative drug to reverse atherosclerotic plaques, for the first time globally.
Jingwei Shida
Only Domestic nCLE: Cellular-Level Imaging Supports Breakthroughs in Respiratory Disease Diagnosis and Treatment
From September 11-14, the Chinese Thoracic Society Annual Conference 2025 was held at the Changsha International Conference Center. Jingwei Shida showcased the only domestic probe-based confocal laser endomicroscopy (nCLE) system for respiratory use.
Multiple BIOPSEE® Beixi® Confocal Academic Conferences Discuss New Advances in Precision Diagnosis of Digestive and Respiratory Diseases
From September 26-28, multiple conferences focused on new advances and technical standards in digestive and respiratory diseases were held. Jingwei Shida, as a pioneer in microscopic medicine, showcased BIOPSEE® Beixi® confocal microscopy endoscopy products.
Haipuluosi
Powerful Collaboration! Haipuluosi and Panomics Reach Strategic Partnership, Opening a New Chapter in Precision Medicine
On September 22, Panomics, a professional immunology testing service company, and Haipuluosi, a leading national high-tech enterprise in precision medicine and gene big data, formally reached a strategic partnership.
11th Anniversary & 1st Anniversary of Hong Kong Medical Laboratory
Recently, Haipuluosi Group announced the 1st anniversary of its Hong Kong medical laboratory.
Haipuluosi Shenzhen, Shangrao, and Hong Kong Labs Achieve CAP-NGSST-A Certification
Recently, the College of American Pathologists (CAP) released the 2025 CAP-NGSST-A quality assessment report. Shenzhen Haipuluosi Medical Laboratory, Shangrao Haipuluosi Laboratory, and HAPLOX GENETECH (HONG KONG) LIMITED all achieved perfect scores.
Standardizing Precision Cancer Diagnosis and Treatment, Innovation Leads the New Journey of Anti-Cancer Efforts
From September 10-14, the 28th CSCO Annual Academic Conference was held in Jinan. Haipuluosi participated as a co-organizer of the CSCO Tumor Biomarker Committee session "Application of Multi-Omics New Technologies in Tumor Research and Practice."
Perfect Score in 2025 NCCL External Quality Assessment for High-Throughput Sequencing of Circulating Tumor DNA Mutations
Recently, the National Center for Clinical Laboratories (NCCL) released the 2025 external quality assessment report for high-throughput sequencing of circulating tumor DNA mutations. Shenzhen Haipuluosi Medical Laboratory achieved a perfect score.
Frontier Biotech
Global First! Frontier Biotech's Dual-Target siRNA Drug FB7011 Brings New Treatment Option for IgA Nephropathy
From September 17-20, the 18th International IgA Nephropathy Symposium (IIgANN 2025) was held in Prague, Czech Republic. Frontier Biotech presented preclinical data for its first-in-class dual-target small nucleic acid drug FB7011 in an oral presentation.
Two Approaches Combined! Chinese Scholars Present New Functional Cure Option for Hepatitis B
From September 8-12, the 2025 International HBV Meeting was held in Berlin, Germany. New research results from the Fudan University-Frontier Biotech Joint Laboratory for Functional Cure of Viral Infections were presented.
Promisement
Launch of New Product Series
Recently, Promisement launched its new fully automated electrochemiluminescence immunoassay analyzers eCL9600, eCL9900, and eCL9900i, redefining testing standards with technological breakthroughs.
Promisement East China Industrialization Base Established in Hexian Puhe Industrial Cooperation Zone, Anhui
On September 21, the groundbreaking ceremony for the "Promisement Hexian In Vitro Diagnostic Reagent Industrialization Project" was held in the Puhe Industrial Cooperation Zone, Hexian County, Ma'anshan City, Anhui Province.
Promisement Shines at CTS 2025
From September 11-14, the Chinese Thoracic Society Annual Conference 2025 (26th Respiratory Disease Academic Conference) was held at the Changsha International Conference Center. Promisement presented its respiratory intervention integrated solution.
Chipscreen
Chidamide Pivotal DEB Study Primary Endpoint Data Released, Significantly Improving Efficacy in First-Line Double-Expressor DLBCL
From September 10-14, the 28th CSCO Annual Academic Conference was held in Jinan. The final results of the primary endpoint of the pivotal Phase III clinical study (DEB study) of Chipscreen's globally first-in-class chidamide (Tradename: Aipusha®) in combination with R-CHOP for double-expressor diffuse large B-cell lymphoma (DE-DLBCL) were announced.
Yahong Pharma
Dr. Pan Ke Invited to Participate in "Fertility Protection for Cancer Patients Under the Construction of a Fertility-Friendly Society"
Recently, Dr. Pan Ke of Yahong Pharma was invited to participate in the preparation of a research report on this topic.
Chief Commercial Officer Ms. Xu Ying Invited to Attend 2025 CIFTIS
On September 14, the "Innovation Progress in Cancer Treatment and New Trends in Drug R&D" forum was successfully held as part of CIFTIS 2025. Ms. Xu Ying, Chief Commercial Officer of Yahong Pharma, was invited to attend and share insights.
First Prescriptions of Onalin® in Multiple Cities, Improving Access to Advanced Breast Cancer Treatment
On September 25, Yahong Pharma announced that its product Onalin® (eribulin mesylate injection) for advanced breast cancer had its first prescriptions in Yancheng, Xuzhou, Xi'an, Chengdu, and Harbin.
03 Portfolio Company New Drug and Device Approvals
Century Kangtai
Meishiji® Orthokeratology Lens Launched
On September 5, at the Century Kangtai booth during CCOS 2025, a launch ceremony themed "Shaping the Future" was held for the AI-optimized rigid gas permeable orthokeratology lens Meishiji®.
Norling Medical
Biaoxin Bio
Respiree Pharma
Budesonide Formoterol Powder Inhaler (II) Receives Clinical Approval
Recently, budesonide formoterol powder inhaler (II) (pipeline code RSG0201) developed by Zhuhai Respiree Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of Shenzhen Respiree Biopharmaceutical Co., Ltd., received Phase III clinical approval from the NMPA.
04 Portfolio Company Honors
Promisement (hs-cTnI STAT, hs-cTnT STAT, NT-proBNP, NT-proBNP STAT): Selected for IFCC official website's reagent analytical performance reference table and interference performance table (v082025)
Huahao Zhongtian (Utidelone Capsules): Selected for Beijing "New Technology, New Product, New Service" certification
Beixin Life: Selected as one of CCI's Top 10 Innovative Enterprises
Chipscreen (Haiou): Selected for China Fund News' 2025 China Listed Company Yinghua Award – Excellent Board Secretary
Orygen Biotech (Plant-derived Recombinant Human Serum Albumin): Selected as No. 1 in 2025 SUPER Top 10 Raw Materials by China International Beauty Expo
Ascentage Pharma, HBM Holdings, Chipscreen: Selected for PharmaCube's China Innovative Drug Decade Glory List – Industry-Leading Biotech Companies
HBM Holdings (Multispecific Antibody Platform Project): Selected for Huayibang's 2025 China Biopharmaceutical Technology Innovation Value List – Top 10 Best Technology Transfer Cases
Qyuns Therapeutics: Selected for Huayibang's 2025 China Biopharmaceutical Technology Innovation Value List – Top 10 Most Growth-Oriented Biologic Drug Enterprises
Xuanzhu Biopharma: Selected for Huayibang's 2025 China Biopharmaceutical Technology Innovation Value List – Top 10 Most Growth-Oriented Small Molecule Innovative Drug Enterprises
Haipuluosi (Dr. Chen Shifu): Selected for Stanford University & Elsevier's 2025 Annual and Lifetime Impact "World's Top 2% Scientists"
Heyuan Bio: Selected for Huayibang's 2025 China Biopharmaceutical Technology Innovation Value List – Top 10 Most Growth-Oriented Cell and Gene Therapy Enterprises
Westlake Omics: Selected for Weilian's 2025 China AI Going Global Future Unicorn Enterprises Top 100
05 Efung Capital Honors
Entrepreneur: Efung Capital – 2025 Most Admired Venture Capital Institutions Top 100
FOFWEEKLY: Efung Capital – 2025 Investment Institution Soft Power Ranking – Medical and Health Top 20
PharmaCube: Efung Capital – China Innovative Drug Decade Glory List – Industry-Leading Biotech Company
Qimingpian: Efung Capital CEO Zhu Pai – 2025 Mid-Year U40 Outstanding Young Investor